Study Shows Kerecis Fish-Skin Outperforms in Diabetic Foot Ulcer Treatment
Kerecis, a leader in the use of fish skin and fatty acids for tissue regeneration, has announced the publication of significant study results in the New England Journal of Medicine Evidence. This research, involving 255 patients across 15 care centers…
Aulos Bioscience to Present Phase 2 Data for AU-007 at SITC Annual Meeting
Aulos Bioscience, an immuno-oncology company focused on advancing cancer care through innovative IL-2 therapeutics, has announced the presentation of encouraging safety and efficacy data from the Phase 2 dose expansion cohorts of its Phase 1/2 clinical trial for AU-007. This…
Peak Mobile Vascular Expands to the Midwest
Peak Mobile Vascular Access is expanding its services to the Midwest, aiming to offer its exceptional vascular access solutions—such as PICC lines, Midlines, and Peripheral IVs—to a wider audience. This strategic move ensures high-quality care and enhanced convenience for both…
FDA Approves Exact Sciences’ Cologuard Plus for Colorectal Cancer Screening
Exact Sciences Corp. (NASDAQ: EXAS), a prominent provider of cancer screening and diagnostic solutions, has announced that the U.S. Food and Drug Administration (FDA) has approved its next-generation multitarget stool DNA test, Cologuard Plus™. This test is now authorized for…
Summit Therapeutics Completes Enrollment in Phase III HARMONi Trial for 2L+ EGFRm NSCLC
Summit Therapeutics Inc. (NASDAQ: SMMT) has announced the completion of patient enrollment in its HARMONi clinical trial. This multi-regional Phase III study evaluates ivonescimab combined with platinum-doublet chemotherapy versus placebo with platinum-doublet chemotherapy for patients with epidermal growth factor receptor…
FDA Approves Neoadjuvant Opdivo® and Chemotherapy for Resectable Non-Small Cell Lung Cancer
Bristol Myers Squibb (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved Opdivo® (nivolumab) for adult patients with resectable non-small cell lung cancer (NSCLC) with tumors ≥4 cm or node-positive, and no known EGFR mutations…
HealthAxis and COPE Health Solutions Form Strategic Partnership to Enhance Value-Based Care
HealthAxis, a leader in healthcare administration technology, has partnered with COPE Health Solutions (CHS), a specialist in value-based care and population health management. This strategic collaboration aims to provide comprehensive, end-to-end solutions for health plans and providers engaged in value-based…
DeepCure to Present In Vivo Data on DC-9476, a Superior BRD4 Inhibitor for Rheumatoid Arthritis
DeepCure, a therapeutics company leveraging AI to discover innovative drugs for inflammation and immune diseases, today announced that it will present data demonstrating that its selective BRD4 (BD2) inhibitor, DC-9476, is more effective than anti-TNF-α treatment in a collagen antibody-induced…
AI Software for Breast Arterial Calcification Scoring Predicts Cardiovascular Outcomes in Women, Study Shows
CureMetrix® has announced a new peer-reviewed study confirming the effectiveness of its investigational AI-enabled software for automated breast arterial calcification (BAC) detection in mammograms. This technology can inform personalized risk predictions for mortality and cardiovascular disease in women. The study…
OS Therapies Completes Last Patient Visit for OST-HER2 Osteosarcoma Phase 2b Trial
OS Therapies (NYSE American: OSTX) announced today that the last patient (Patient #41) enrolled in the AOST-2121 clinical trial (NCT04974008) for OST-HER2 in recurrent, resected osteosarcoma has completed their final radiographical evaluation at 52 weeks, marking the end of the…
Charles River Showcases Translational Expertise at Neuroscience 2024
Charles River Laboratories International, Inc. (NYSE: CRL) has announced that its neuroscience drug discovery team will present 18 scientific posters at Neuroscience 2024, the annual meeting of the Society for Neuroscience (SfN). These presentations will include both independent research and…
Digbi Health to Unveil Study on Gut Microbiome and GLP-1 Production at 2024 Obesity Society Conference
Digbi Health, a leader in Precision Biology and personalized healthcare, has been invited to present a groundbreaking study at the Obesity Society Conference. The research highlights how the Digbi Health program effectively modifies the gut microbiome to boost the body’s…